De Novo vs. 510(k): How to Choose the Right FDA Pathway When There's No Clear Predicate

The Predicate Problem: When 510(k) Becomes a Trap

One of the most consequential decisions a medical device company makes is choosing its FDA market authorization pathway. For many startups and even seasoned regulatory teams, the instinct is to reach for a 510(k) -- it is faster, cheaper, and more familiar. But when your device is genuinely novel, forcing a 510(k) submission without a solid predicate can cost you more time and money than simply taking the right path from the start.

The De Novo classification process, established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act and codified at 21 CFR Part 860, Subpart D, exists precisely for this scenario. It is not a consolation prize. Used strategically, it is a powerful tool that establishes your device as a predicate for future 510(k) submitters -- including your competitors.

So how do you decide which pathway fits your device? Here is a practical framework built on regulatory reality, not optimism.

Understanding the Core Distinction

A 510(k) clearance requires demonstrating substantial equivalence to a legally marketed predicate device under 21 CFR 807.87(f). That predicate must share the same intended use and have the same or similar technological characteristics -- or, if the characteristics differ, those differences must not raise new questions of safety and effectiveness.

De Novo, by contrast, is designed for novel, low-to-moderate risk devices (Class I or Class II) for which no valid predicate exists. Rather than claiming equivalence, you are asking FDA to establish a new classification regulation with special controls that provide reasonable assurance of safety and effectiveness.

The critical inflection point: if your device has no legally marketed predicate, or if the closest predicate is so distant that the substantial equivalence argument is a stretch, you are not looking at a 510(k) situation. You are looking at De Novo -- or potentially a PMA, if the risk profile is higher.

Five Signals That De Novo Is Your Pathway

• Your device uses a novel technology principle. If your mechanism of action, sensing modality, or therapeutic approach has not been reviewed by FDA in a cleared or approved device, a predicate search will likely come up empty or yield only superficially similar devices.
• The closest 510(k)-cleared device has a materially different intended use. Stretching intended use comparisons is one of the most common reasons FDA issues a Not Substantially Equivalent (NSE) determination. An NSE does not kill your program, but it does force you into De Novo anyway -- after you have already spent time and submission fees.
• Your device introduces new risks that require new special controls. FDA's De Novo process allows the agency to craft device-specific special controls -- performance testing, labeling requirements, postmarket surveillance -- that appropriately mitigate risks your device category has never addressed before.
• You are in an emerging category such as AI/ML-driven diagnostics or digital therapeutics. FDA's 2023 action plan for AI/ML-based Software as a Medical Device (SaMD) explicitly acknowledges the limitations of the current 510(k) framework for these technologies. De Novo has been the pathway for a number of landmark AI-based device authorizations.
• You want to own the predicate. This is underappreciated. A successful De Novo grant means FDA creates a new classification regulation. Every competitor who later brings a substantially equivalent device to market will need to cite your device as predicate in their 510(k). That is a durable competitive advantage built into the regulatory record.

When 510(k) Still Wins -- Even Without an Obvious Predicate

De Novo is not always the answer when a predicate is hard to find. In some cases, a thorough predicate search using FDA's 510(k) database and the Product Classification database reveals a cleared device with a stronger connection than initially apparent. Split predicate strategies -- where you cite one device for intended use and a second for technological characteristics -- are explicitly recognized by FDA in its guidance document 'Recommended Approaches to Integration of Independent Review Panels' and the 2014 'De Novo Classification Process' guidance.

If your device differs from predicate only in software features, materials, or ergonomics, and those differences do not introduce new safety questions, a 510(k) with strong comparative testing data may be entirely defensible. The key is building that argument on evidence, not assumption.

The Pre-Submission Meeting: Your Most Important First Step

Before committing to either pathway, request a Pre-Submission (Q-Sub) meeting with FDA under the process described in the guidance document 'Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program' (updated 2023). A Q-Sub allows you to present your proposed classification rationale, describe your device, and get written FDA feedback before you spend resources on a full submission. This is not optional for novel devices -- it is how experienced regulatory teams de-risk the pathway decision entirely.

In your Q-Sub request, clearly articulate why no predicate exists, describe the risk profile of your device, and propose the classification you believe is appropriate with supporting rationale. FDA's written response becomes part of your submission record and significantly reduces the likelihood of a major deficiency letter.

Bottom Line: Pathway Selection Is a Strategic Decision

Defaulting to 510(k) because it feels faster is one of the most expensive mistakes a device company can make when the predicate landscape is thin. De Novo is a legitimate, well-defined pathway with a clear statutory basis and a growing body of granted requests across diagnostics, digital health, and novel therapeutics. Choosing it proactively -- with a strong risk classification rationale, well-designed performance data, and a proposed set of special controls -- positions your company for faster review cycles and a stronger market position post-authorization.

The right pathway is not the one that looks easiest at the outset. It is the one that matches your device's actual risk profile and gets you to market with a durable, defensible authorization.

Ready to Map Your FDA Pathway?

At ADB Consulting and CRO Inc., Andre Butler and the team work directly with medical device startups and regulatory affairs professionals to develop submission strategies grounded in FDA science and regulatory precedent -- not guesswork. Whether you are still evaluating De Novo versus 510(k) or preparing a Q-Sub package, we can help you move faster and smarter.

Book a free discovery call at adbccro.com and get clarity on your regulatory pathway before your next development milestone.

If this applies to your program, our 510(k) Gap Assessment walks through the process in detail.